A brain cancer vaccine developed at Roswell Park Comprehensive Cancer Center appears to be safe and significantly extends survival in newly diagnosed glioblastoma patients, according to a Phase 2A single-arm clinical trial. The study, “Phase 2A Study of SurVaxM Plus Adjuvant Temozolomide for Newly Diagnosed Glioblastoma,” appears this week in the Journal of Clinical Oncology. Manmeet Ahluwalia, MD, MBA, Fernandez Family Foundation Endowed Chair in Cancer Research, Chief of Medical Oncology, Deputy Director and Chief Scientific Officer of Miami Cancer Institute, served as overall Principal Investigator.

Following an international search, Roswell Park Comprehensive Cancer Center has promoted and appointed Joyce Ohm, PhD, as Chair of Cancer Genetics and Genomics as well as the John & Santa Palisano Endowed Chair of Cancer Genetics. She previously served as interim chair of the department.

During the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13 in New Orleans, Louisiana, Roswell Park Comprehensive Cancer Center pre-doctoral trainee Payal Goala, MS, BS, will present research findings that hold potential to help address two significant toxicities associated with Chimeric Antigen Receptor (CAR) T-cell therapy.

Eunice S. Wang, MD, Chief of Leukemia at Roswell Park Comprehensive Cancer Center, led a research effort that supports the addition of gemtuzumab ozogamicin—a CD33-directed antibody-drug conjugate—to standard induction chemotherapy for the treatment of newly-diagnosed intermediate-risk cytogenetic acute myeloid leukemia (AML). The study will be highlighted during an oral presentation at the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13 in New Orleans, Louisiana.

While tobacco smoking has been shown to reduce the efficacy of radiation therapy among patients with head and neck cancers, a new study from Roswell Park Comprehensive Cancer aims to examines cancer treatment outcomes of smokers.

Roswell Park Comprehensive Cancer Center experts from a variety of specialties will share practice-changing discoveries and research advances in hematology and hematologic cancers at the 64th annual meeting of the American Society of Hematology (ASH), held December 10-13 in New Orleans, Louisiana. Roswell Park researchers and physician-scientists in leukemia, lymphoma, and myelodysplastic syndromes were invited to give podium presentations or lead educational sessions during the meeting.